Immune engineering and modulation are the basis of a novel but powerful tool to treat immune diseases using virus-like particles (VLPs). VLPs are formed by the viral capsid without genetic material making them non-infective. However, they offer a wide variety of possibilities as antigen-presenting platforms, resulting in high immunogenicity and high efficacy in immune modulation, with low allergenicity. Both animal and plant viruses are being studied for use in the treatment of food allergies. These formulations are combined with adjuvants, T-stimulatory epitopes, TLR ligands, and other immune modulators to modulate or enhance the immune response toward the presented allergen. Here, the authors present an overview of VLP production systems, their immune modulation capabilities, and the applicability of actual VLP-based formulations targeting allergic diseases.
Background: Skin barrier disruption is increasingly recognised as a critical determinant of food allergy development, yet the molecular events linking cutaneous damage to systemic sensitisation remain incompletely defined. Ara h 2, a major peanut allergen, displays unusually high allergenic potency, but the early cutaneous mechanisms that confer immunogenicity is poorly understood. Objective: To elucidate how lipid–protein interactions and epigenetic remodelling cooperate to drive epicutaneous sensitisation to Ara h 2 following skin barrier disruption. Methods: A mouse model of repeated epicutaneous exposure to recombinant Ara h 2, alone or complexed with roasted‑peanut lipids, was combined with histology, NF‑κB reporter assays, hydrophobic‑plate binding, nanoparticle‑assisted LC‑QTOF MS, isothermal titration calorimetry, molecular docking and molecular dynamics simulations. Chromatin changes were assessed by H3K4me2 ChIP‑seq on pooled skin samples. Results: Skin barrier disruption enabled Ara h 2 to induce systemic inflammation, CD45+ infiltration in multiple organs, and allergen‑specific IgG1. Ara h 2 selectively bound sphingoid‑base lipids present in roasted peanut and damaged skin, including a putative C16 1‑deoxysphinganine identified by LC‑QTOF MS. Lipid association conferred NF‑κB activation and promoted localisation of Ara h 2 to ceramide‑rich epidermal niches enriched in CD207+ cells. Repeated exposure induced promoter‑proximal H3K4me2 and H3K9me1 gains, with enrichment of pathways linked to glycosphingolipid metabolism, antigen presentation, cytokine signalling and epithelial remodelling. Conclusion: Lipid binding and epigenetic remodelling act as dual, complementary drivers of epicutaneous sensitisation to Ara h 2. These findings identify allergen–lipid interactions and chromatin‑state modulation as potential therapeutic targets to prevent or attenuate food allergy development.